Ligand Pharmaceuticals Inc. Stock OTC Bulletin Board
Equities
US53220K1815
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 08 | Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties | MT |
Jul. 08 | Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024 | CI |
Financials (USD)
Sales 2024 * | 149M | Sales 2025 * | 169M | Capitalization | 1.74B |
---|---|---|---|---|---|
Net income 2024 * | 96M | Net income 2025 * | 61M | EV / Sales 2024 * | 11.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.3 x |
P/E ratio 2024 * |
18.7
x | P/E ratio 2025 * |
27.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.65% |
Latest transcript on Ligand Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
1st Jan change | Capi. | |
---|---|---|
+63.05% | 856B | |
+38.99% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+13.60% | 244B | |
+5.44% | 234B | |
+16.58% | 226B | |
+14.63% | 177B |